Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cells are more precise and sophisticated in their ability ...
Apr 15, 2022
0
27
Chimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and lymphomas, but there are no successful immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal cancers (GICs) yet. ...
Mar 24, 2022
0
47
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, ...
Mar 21, 2022
0
44
The first FDA-approved gene therapies are living drugs: immune cells taken from cancer patients engineered to target tumor cells. However, for many patients, these advanced therapies do not result in a long-lasting remission. ...
Mar 16, 2022
0
95
Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted ...
Feb 2, 2022
0
87
Despite high remission rates for patients treated with T cells that are supercharged in laboratories into elite cancer warriors, there is still a considerable population of patients who eventually relapse, their cancers invariably ...
An experimental immunotherapy can temporarily reprogram patients' immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new ...
Jan 6, 2022
0
562
Newly designed chimeric antigen receptor (CAR) T-cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies, especially when produced under place-of-care manufacturing which is ...
Dec 20, 2021
0
3
Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, ...
Dec 13, 2021
0
1
St. Jude Children's Research Hospital is testing a treatment for cancer called a chimeric antigen receptor (CAR) T cell. T cells are a kind of immune cell. They help fight infections and diseases such as cancer. Scientists ...
Nov 30, 2021
0
21
